Literature DB >> 11897604

Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection.

Azzam Saleh-Mghir1, Nourdine Ameur, Claudette Muller-Serieys, Farid Ismael, Françoise Lemaitre, Laurent Massias, Céline Feger, Rémy Bléton, Anne-Claude Crémieux.   

Abstract

We compared the efficacies of quinupristin-dalfopristin (Q-D; 30 mg/kg of body weight every 8 h) and vancomycin (60 mg/kg twice daily), alone or in combination with rifampin (10 mg/kg twice daily), in a rabbit model of methicillin-resistant Staphylococcus aureus knee prosthesis infection. In contrast to vancomycin, Q-D significantly reduced the mean log(10) CFU per gram of bone versus that for the controls. The combination of rifampin with either Q-D or vancomycin was significantly more effective than monotherapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11897604      PMCID: PMC127098          DOI: 10.1128/AAC.46.4.1122-1124.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

1.  Wound infection in hip and knee arthroplasty.

Authors:  W J Gaine; N A Ramamohan; N A Hussein; M G Hullin; S W McCreath
Journal:  J Bone Joint Surg Br       Date:  2000-05

2.  Efficacy of sparfloxacin and autoradiographic diffusion pattern of [14C]Sparfloxacin in experimental Staphylococcus aureus joint prosthesis infection.

Authors:  A C Crémieux; A S Mghir; R Bleton; M Manteau; N Belmatoug; L Massias; L Garry; N Sales; B Mazière; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

3.  Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics.

Authors:  V Zarrouk; B Bozdogan; R Leclercq; L Garry; C Feger; C Carbon; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

Review 4.  Chemotherapy for gram-positive nosocomial sepsis.

Authors:  M J Wood
Journal:  J Chemother       Date:  1999-12       Impact factor: 1.714

5.  The effects of exposure at constant (1 h) or exponentially decreasing concentrations of quinupristin/dalfopristin on biofilms of Gram-positive bacteria.

Authors:  S Gander; R Finch
Journal:  J Antimicrob Chemother       Date:  2000-07       Impact factor: 5.790

6.  Analysis of 42 cases of septicemia caused by an epidemic strain of methicillin-resistant Staphylococcus aureus: evidence of resistance to vancomycin.

Authors:  J Burnie; R Matthews; A Jiman-Fatami; P Gottardello; S Hodgetts; S D'arcy
Journal:  Clin Infect Dis       Date:  2000-10-04       Impact factor: 9.079

7.  Treatment of experimental staphylococcal infections: effect of rifampin alone and in combination on development of rifampin resistance.

Authors:  G L Mandell; D R Moorman
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

8.  Rifampin resistance. Development during the therapy of methicillin-resistant Staphylococcus aureus infection.

Authors:  R H Eng; S M Smith; M Tillem; C Cherubin
Journal:  Arch Intern Med       Date:  1985-01

Review 9.  Lessons learned from animal models of osteomyelitis.

Authors:  C W Norden
Journal:  Rev Infect Dis       Date:  1988 Jan-Feb

10.  Treatment of experimental chronic osteomyelitis due to Staphylococcus aureus with teicoplanin.

Authors:  C W Norden; K Niederreiter; E M Shinners
Journal:  Infection       Date:  1986 May-Jun       Impact factor: 3.553

View more
  15 in total

1.  Antimicrobial therapy for bone and joint infections.

Authors:  Saima Aslam; Rabih O Darouiche
Journal:  Curr Infect Dis Rep       Date:  2009-01       Impact factor: 3.725

2.  Ceftobiprole efficacy in vitro against Panton-Valentine leukocidin production and in vivo against community-associated methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits.

Authors:  Azzam Saleh-Mghir; Oana Dumitrescu; Aurélien Dinh; Yassine Boutrad; Laurent Massias; Emilie Martin; François Vandenesch; Jérôme Etienne; Gérard Lina; Anne Claude Crémieux
Journal:  Antimicrob Agents Chemother       Date:  2012-10-01       Impact factor: 5.191

3.  Adjunctive rifampin is crucial to optimizing daptomycin efficacy against rabbit prosthetic joint infection due to methicillin-resistant Staphylococcus aureus.

Authors:  Azzam Saleh-Mghir; Claudette Muller-Serieys; Aurélien Dinh; Laurent Massias; Anne-Claude Crémieux
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

4.  Ceftaroline-Fosamil efficacy against methicillin-resistant Staphylococcus aureus in a rabbit prosthetic joint infection model.

Authors:  Laure Gatin; Azzam Saleh-Mghir; Jason Tasse; Idir Ghout; Frédéric Laurent; Anne-Claude Crémieux
Journal:  Antimicrob Agents Chemother       Date:  2014-08-18       Impact factor: 5.191

Review 5.  Modality of bacterial growth presents unique targets: how do we treat biofilm-mediated infections?

Authors:  Paul D Fey
Journal:  Curr Opin Microbiol       Date:  2010-09-29       Impact factor: 7.934

Review 6.  Clinical pharmacokinetics of quinupristin/dalfopristin.

Authors:  David T Bearden
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

7.  Teicoplanin-containing cement spacers for treatment of experimental Staphylococcus aureus joint prosthesis infection.

Authors:  Farid Ismael; Rémy Bléton; Azzam Saleh-Mghir; Sophie Dautrey; Laurent Massias; Anne-Claude Crémieux
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

Review 8.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

Review 9.  Daptomycin in bone and joint infections: a review of the literature.

Authors:  Dennis A K Rice; Luke Mendez-Vigo
Journal:  Arch Orthop Trauma Surg       Date:  2008-11-07       Impact factor: 3.067

10.  A Strong Synergy Between the Thiopeptide Bacteriocin Micrococcin P1 and Rifampicin Against MRSA in a Murine Skin Infection Model.

Authors:  Kirill V Ovchinnikov; Christian Kranjec; Amar Telke; Morten Kjos; Tage Thorstensen; Siegfried Scherer; Harald Carlsen; Dzung B Diep
Journal:  Front Immunol       Date:  2021-07-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.